| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ulrike C Lange | Q89669106 |
| P2093 | author name string | Carine Van Lint | |
| Roxane Verdikt | |||
| Amina Ait-Ammar | |||
| P2860 | cites work | DNA methylation patterns and epigenetic memory | Q22065780 |
| EUKARYOTIC CYTOSINE METHYLTRANSFERASES | Q22255656 | ||
| The roles of DNA, RNA and histone methylation in ageing and cancer | Q91595196 | ||
| Between a shock and a hard place: challenges and developments in HIV latency reversal | Q91707985 | ||
| Unexpected Mutations in HIV-1 That Confer Resistance to the Tat Inhibitor Didehydro-Cortistatin A | Q91753572 | ||
| Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations | Q92697820 | ||
| Clones of infected cells arise early in HIV-infected individuals | Q92884455 | ||
| Deep latency: A new insight into a functional HIV cure | Q92945663 | ||
| Chromatin Regulation and the Histone Code in HIV Latency | Q95355768 | ||
| Transcription factors as readers and effectors of DNA methylation | Q38915083 | ||
| Nuclear landscape of HIV-1 infection and integration | Q39035944 | ||
| Hepatitis virus infection affects DNA methylation in mice with humanized livers. | Q39067748 | ||
| Position effects influence HIV latency reversal | Q39167914 | ||
| Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation | Q39173734 | ||
| Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. | Q39362365 | ||
| Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy | Q39369360 | ||
| The Molecular Basis for Human Immunodeficiency Virus Latency | Q39439255 | ||
| HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP | Q39703646 | ||
| DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcr | Q39711686 | ||
| Targeted Immune Interventions for an HIV-1 Cure | Q40048864 | ||
| HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. | Q40050048 | ||
| Detection, characterization and regulation of antisense transcripts in HIV-1. | Q40073362 | ||
| The relevance of post-transcriptional mechanisms in HIV latency reversal | Q40092621 | ||
| A role for LEDGF/p75 in targeting HIV DNA integration | Q40346940 | ||
| Identification of HIV infection-related DNA methylation sites and advanced epigenetic aging in HIV-positive, treatment-naive U.S. veterans | Q40421802 | ||
| Long-Term Nonprogressor and Elite Controller Patients Who Control Viremia Have a Higher Percentage of Methylation in Their HIV-1 Proviral Promoters than Aviremic Patients Receiving Highly Active Antiretroviral Therapy | Q41167388 | ||
| Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. | Q41880147 | ||
| Dynamics and memory of heterochromatin in living cells. | Q41940196 | ||
| Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency | Q42059823 | ||
| NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation | Q42128724 | ||
| HIV-1 tat transcriptional activity is regulated by acetylation | Q42163503 | ||
| In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment. | Q42381408 | ||
| Human immunodeficiency virus may encode a novel protein on the genomic DNA plus strand | Q42657622 | ||
| Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. | Q42755157 | ||
| HIV cure and eradication: how will we get from the laboratory to effective clinical trials? | Q45868572 | ||
| HIV integration sites and implications for maintenance of the reservoir | Q47329569 | ||
| Transcription: Insights From the HIV-1 Promoter | Q47557756 | ||
| Unraveling the Complex Epigenetic Mechanisms that Regulate Gene Activity | Q50100294 | ||
| Novel Latency Reversal Agents for HIV-1 Cure | Q52816327 | ||
| Targeting the Latent Reservoir for HIV-1. | Q54210140 | ||
| Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T Cells. | Q54224088 | ||
| Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR. | Q55265466 | ||
| The role of integration and clonal expansion in HIV infection: live long and prosper | Q57799661 | ||
| Organizational principles of 3D genome architecture | Q58115647 | ||
| Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1 | Q58377824 | ||
| HIV infection alters the human epigenetic landscape | Q59350860 | ||
| Challenges in Quantifying Cytosine Methylation in the HIV Provirus | Q61445483 | ||
| Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion | Q61796320 | ||
| Impact of LEDGIN treatment during virus production on residual HIV-1 transcription | Q64086928 | ||
| Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat | Q64107839 | ||
| Control of viral infections by epigenetic-targeted therapy | Q64110985 | ||
| Establishment of latent HIV-1 reservoirs: what do we really know? | Q64231598 | ||
| Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy | Q77890124 | ||
| Host factors regulating post-integration latency of HIV | Q81627002 | ||
| Longitudinal variation in human immunodeficiency virus long terminal repeat methylation in individuals on suppressive antiretroviral therapy | Q90098575 | ||
| Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription | Q91563978 | ||
| Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing | Q24294385 | ||
| Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat | Q24537275 | ||
| Epigenetic transcriptional repression of cellular genes by a viral SET protein | Q24618421 | ||
| Regulation of chromatin by histone modifications | Q24635070 | ||
| Comparison of 5' and 3' long terminal repeat promoter function in human immunodeficiency virus | Q24646050 | ||
| Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation | Q24678487 | ||
| COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells | Q24806175 | ||
| The interplay of histone modifications - writers that read | Q26782196 | ||
| Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure | Q26999858 | ||
| Genome regulation by long noncoding RNAs. | Q27691812 | ||
| The language of covalent histone modifications | Q27860931 | ||
| Chromatin modifications and their function | Q27861067 | ||
| Epigenetic impact of infection on carcinogenesis: mechanisms and applications | Q28066519 | ||
| Retroviral integration: Site matters: Mechanisms and consequences of retroviral integration site selection | Q28088514 | ||
| The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation | Q28361880 | ||
| Epigenetic regulation of HIV-1 latency by cytosine methylation | Q28475636 | ||
| Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells | Q28536951 | ||
| Perceptions of epigenetics | Q29547310 | ||
| HIV-1 integration in the human genome favors active genes and local hotspots | Q29618457 | ||
| HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation | Q29619611 | ||
| Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity | Q33220546 | ||
| Interfering RNA and HIV: reciprocal interferences | Q33372109 | ||
| CpG methylation controls reactivation of HIV from latency | Q33495565 | ||
| Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. | Q33604848 | ||
| An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription | Q33724213 | ||
| Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's. | Q33768729 | ||
| Infection with Human Immunodeficiency Virus Type 1 Upregulates DNA Methyltransferase, Resulting in De Novo Methylation of the Gamma Interferon (IFN-γ) Promoter and Subsequent Downregulation of IFN-γ Production | Q33777676 | ||
| Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation | Q33846679 | ||
| Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. | Q33883423 | ||
| The Human Immunodeficiency Virus 1 ASP RNA promotes viral latency by recruiting the Polycomb Repressor Complex 2 and promoting nucleosome assembly | Q33893725 | ||
| Immunologic strategies for HIV-1 remission and eradication | Q33896523 | ||
| Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. | Q33919346 | ||
| Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. | Q34057748 | ||
| Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency | Q34090863 | ||
| An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription | Q34289422 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| A proteomic glimpse into the initial global epigenetic changes during HIV infection | Q34344844 | ||
| Nuclear architecture dictates HIV-1 integration site selection. | Q34465264 | ||
| HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection | Q34502840 | ||
| The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit | Q34544409 | ||
| Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy | Q34607544 | ||
| Towards an HIV cure: a global scientific strategy | Q34640562 | ||
| HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells | Q34672568 | ||
| DNA methylation and gene silencing in cancer: which is the guilty party? | Q34770507 | ||
| Epigenetic heterogeneity in HIV-1 latency establishment | Q34877762 | ||
| HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. | Q34985945 | ||
| Non-coding RNAs as regulators of gene expression and epigenetics. | Q34986526 | ||
| Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA | Q35080754 | ||
| Viral Genes and Methylation | Q35118506 | ||
| Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen | Q35123088 | ||
| Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. | Q35192959 | ||
| HIV-1 integration landscape during latent and active infection | Q35211469 | ||
| Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells | Q35213780 | ||
| Non-coding RNAs and HIV: viral manipulation of host dark matter to shape the cellular environment. | Q35219072 | ||
| RNA-mediated epigenetic regulation of gene expression | Q35223649 | ||
| Polarized expression of the membrane ASP protein derived from HIV-1 antisense transcription in T cells | Q35241307 | ||
| A hardwired HIV latency program | Q35400385 | ||
| Epigenetic modulations in activated cells early after HIV-1 infection and their possible functional consequences. | Q35601948 | ||
| LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing | Q35823707 | ||
| The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency | Q35829282 | ||
| HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications | Q35914779 | ||
| Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy | Q35943698 | ||
| HIV-1-encoded antisense RNA suppresses viral replication for a prolonged period | Q36136773 | ||
| Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir | Q36318184 | ||
| HIV latency: experimental systems and molecular models. | Q36585019 | ||
| In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. | Q36592182 | ||
| Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals | Q36596027 | ||
| Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo | Q36607484 | ||
| A Minor Subset of Super Elongation Complexes Plays a Predominant Role in Reversing HIV-1 Latency | Q36709227 | ||
| HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression | Q36781531 | ||
| DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1 | Q36828450 | ||
| Methylation as a modulator of expression of human immunodeficiency virus | Q36886830 | ||
| What Integration Sites Tell Us about HIV Persistence | Q36987230 | ||
| Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation | Q37010047 | ||
| LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV | Q37035177 | ||
| MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals | Q37102282 | ||
| Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy | Q37161557 | ||
| Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA. | Q37198065 | ||
| Defective proviruses rapidly accumulate during acute HIV-1 infection | Q37239064 | ||
| Broad activation of latent HIV-1 in vivo | Q37260309 | ||
| Transcriptional competence of the integrated HIV-1 provirus at the nuclear periphery | Q37304680 | ||
| Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies | Q37644561 | ||
| International AIDS Society global scientific strategy: towards an HIV cure 2016. | Q37661770 | ||
| Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency | Q37695602 | ||
| Epigenetic reprogramming of host genes in viral and microbial pathogenesis | Q37781197 | ||
| The control of HIV transcription: keeping RNA polymerase II on track | Q37958430 | ||
| LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 - 2014). | Q38199193 | ||
| Regulation of HIV-1 latency by chromatin structure and nuclear architecture. | Q38235100 | ||
| Multiple Origins of Virus Persistence during Natural Control of HIV Infection | Q38379102 | ||
| Reversal of Latency as Part of a Cure for HIV-1. | Q38382980 | ||
| HIV persistence: clonal expansion of cells in the latent reservoir | Q38669409 | ||
| 5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals | Q38758956 | ||
| Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents? | Q38773858 | ||
| The molecular hallmarks of epigenetic control | Q38877902 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P577 | publication date | 2020-02-11 | |
| 2020-04-01 | |||
| P1433 | published in | Seminars in Immunopathology | Q15724576 |
| P1476 | title | Epigenetic crosstalk in chronic infection with HIV-1 |
| Q92137391 | Infection-induced epigenetic changes and their impact on the pathogenesis of diseases | cites work | P2860 |
Search more.